Mc Callion Orla
General Counsel at ULTIMOVACS ASA
Net worth: - $ as of 2024-05-30
Mc Callion Orla active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ULTIMOVACS ASA | General Counsel | 2021-09-30 | - |
Career history of Mc Callion Orla
Former positions of Mc Callion Orla
| Companies | Position | Start | End |
|---|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | General Counsel | 2012-09-30 | 2021-09-30 |
Training of Mc Callion Orla
| Queen's University | Doctorate Degree |
Statistics
International
| Norway | 2 |
| Sweden | 2 |
| Canada | 2 |
Operational
| General Counsel | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ULTIMOVACS ASA | Health Technology |
| Private companies | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Mc Callion Orla
- Experience
